Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025On track to initiate U.S.
X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update
X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the third quarter ended September 30, 2024 and highlighted recent and key upcoming expected milestones.
Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results
" I’m honored to join Innate Pharma at such a pivotal moment in its evolution,”said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “ We achieved notable regul
Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights
AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, to complete enrollment in the first half of 2025Expect to announce topline results
Eyenovia Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, today announced its financial and operating results for the third quarter ended September 30,
Hurricane forecast: Florida could see a rare and major threat or a sloppy system
Do we really have to go through all of this again? This question is on the minds of millions of Floridians as hurricane ...
The Cool Down on MSN2d
Remote island trapped in 'vortex' of plastic — and they're not the ones to blame
Easter Island, also known as Rapa Nui by the locals, is a remote island off the coast of Chile. As of 2023, its population ...
National Hurricane Center tracking system in Caribbean. Will it become Tropical Storm Patty?
A system in Caribbean has a high chance for development between Oct. 31 and Nov. 4, according to AccuWeather. Will it become ...
A named storm could develop in the Caribbean by Monday. What to know.
Meteorologists are tracking a disturbance in the Caribbean that could become the Atlantic’s next — and perhaps last — named ...
Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis
SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic ...
Bryan Norcross: Forecast consensus shows a tropical system tracking toward the Gulf next week
Long-range computer forecasts are in much better agreement that a disturbance, tropical depression, or perhaps Tropical Storm ...
Nasdaq19d
Gyre Therapeutics Breaks Above 200-Day Moving Average - Bullish for GYRE
In trading on Friday, shares of Gyre Therapeutics Inc (Symbol: GYRE) crossed above their 200 day moving average of $14.43, changing hands as high as $14.83 per share. Gyre Therapeutics Inc ...
Yahoo Finance8mon
Gyre Therapeutics, Inc. (GYRE)
SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with ...
CNN10mon
Gyre Therapeutics Inc
Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated ...